Table 2.
Cohort 2: Highest Correlations Between miRNAs and Clinical/MRI Data
| miRNA | Spearman Correlation Coefficienta |
Protective/Pathogenic miRNA |
P Value | |
|---|---|---|---|---|
| Uncorrected | Correctedb | |||
| Brain T2LV | ||||
| hsa.miR.210.3p | 0.359 | Pathogenic | .001 | .50 |
| hsa.miR.362.5p | −0.333 | Protective | .003 | .50 |
| hsa.miR.92a.1.5p | 0.327 | Pathogenic | .003 | .50 |
| hsa.miR.1914.3p | 0.324 | Pathogenic | .004 | .50 |
| hsa.miR.330.5p | −0.305 | Protective | .006 | .66 |
| hsa.miR.577 | 0.296 | Pathogenic | .008 | .66 |
| hsa.miR.572 | −0.292 | Protective | .009 | .66 |
| hsa.miR.154.3p | 0.281 | Pathogenic | .01 | .66 |
| hsa.miR.30b.5p | −0.279 | Protective | .01 | .66 |
| hsa.miR.671.5p | −0.274 | Protective | .02 | .66 |
| Brain T1:T2 Ratio | ||||
| hsa.miR.548a.3p | −0.365 | Protective | <.001 | .18 |
| hsa.miR.515.5p | −0.348 | Protective | .002 | .18 |
| hsa.miR.27b.3p | −0.348 | Protective | .002 | .18 |
| hsa.miR.223.3p | −0.345 | Protective | .002 | .18 |
| hsa.miR.574.3p | −0.344 | Protective | .002 | .18 |
| hsa.miR.23b.3p | −0.342 | Protective | .002 | .18 |
| hsa.miR.23a.3p | −0.337 | Protective | .002 | .18 |
| hsa.miR.197.3p | −0.332 | Protective | .003 | .18 |
| hsa.miR.25.5p | 0.323 | Pathogenic | .003 | .18 |
| hsa.miR.1271.5p | −0.317 | Protective | .005 | .25 |
| BPV | ||||
| hsa.miR.484 | −0.392 | Pathogenic | <.001 | .19 |
| hsa.miR.627.5p | 0.335 | Protective | .003 | .41 |
| hsa.miR.671.5p | 0.330 | Protective | .003 | .41 |
| hsa.miR.320b | −0.323 | Pathogenic | .004 | .41 |
| hsa.miR.362.5p | 0.322 | Protective | .004 | .41 |
| hsa.miR.30a.3p | −0.317 | Pathogenic | .004 | .40 |
| hsa.miR.548d.5p | 0.300 | Protective | .007 | .48 |
| hsa.miR.486.5p | −0.288 | Pathogenic | .01 | .48 |
| hsa.miR.132.5p | 0.287 | Protective | .01 | .48 |
| hsa.miR.135a.5p | 0.281 | Protective | .01 | .48 |
| cGMV | ||||
| hsa.miR.484 | −0.386 | Pathogenic | <.001 | .24 |
| hsa.miR.610 | −0.329 | Pathogenic | .003 | .58 |
| hsa.miR.627.5p | 0.312 | Protective | .005 | .58 |
| hsa.miR.340.5p | 0.306 | Protective | .006 | .58 |
| hsa.miR.188.5p | −0.302 | Pathogenic | .007 | .58 |
| hsa.miR.7.5p | −0.301 | Pathogenic | .007 | .58 |
| hsa.miR.934 | −0.285 | Pathogenic | .01 | .58 |
| hsa.miR.556.5p | −0.279 | Pathogenic | .01 | .58 |
| hsa.miR.615.3p | 0.277 | Protective | .01 | .58 |
| hsa.miR.25.3p | −0.277 | Pathogenic | .01 | .58 |
| Spinal T2LV | ||||
| hsa.miR.132.5p | −0.349 | Protective | .002 | .88 |
| hsa.miR.548j.5p | 0.325 | Pathogenic | .003 | .88 |
| hsa.miR.937.3p | 0.305 | Pathogenic | .006 | .88 |
| hsa.miR.342.5p | 0.285 | Pathogenic | .01 | .88 |
| hsa.miR.433.3p | 0.273 | Pathogenic | .02 | .88 |
| hsa.miR.150.5p | 0.263 | Pathogenic | .02 | .88 |
| hsa.miR.155.5p | 0.263 | Pathogenic | .02 | .88 |
| hsa.miR.10a.5p | 0.261 | Pathogenic | .02 | .88 |
| hsa.miR.202.5p | −0.254 | Protective | .02 | .88 |
| hsa.miR.943 | 0.244 | Pathogenic | .03 | .88 |
| Normalized UCCA | ||||
| hsa.miR.130b.3p | −0.350 | Pathogenic | .002 | .56 |
| hsa.miR.135a.5p | 0.337 | Protective | .002 | .56 |
| hsa.miR.148b.5p | 0.329 | Protective | .003 | .56 |
| hsa.miR.374a.5p | 0.272 | Protective | .02 | .86 |
| hsa.miR.101.3p | 0.261 | Protective | .02 | .86 |
| hsa.miR.1538 | −0.249 | Pathogenic | .03 | .86 |
| hsa.miR.1468.5p | −0.247 | Pathogenic | .03 | .86 |
| hsa.miR.1247.5p | 0.245 | Protective | .03 | .86 |
| hsa.miR.190a.5p | 0.245 | Protective | .03 | .86 |
| hsa.miR.30a.3p | −0.242 | Pathogenic | .03 | .86 |
| EDSS | ||||
| hsa.miR.199a.5p | −0.380 | Protective | <.001 | .23 |
| hsa.miR.25.5p | 0.350 | Pathogenic | .002 | .23 |
| hsa.miR.551b.3p | −0.350 | Protective | .002 | .23 |
| hsa.miR.496 | −0.349 | Protective | .002 | .23 |
| hsa.miR.301a.3p | −0.323 | Protective | .004 | .37 |
| hsa.miR.181c.3p | −0.320 | Protective | .004 | .37 |
| hsa.miR.301b | −0.308 | Protective | .006 | .37 |
| hsa.miR.136.3p | −0.305 | Protective | .006 | .37 |
| hsa.miR.15a.5p | 0.298 | Pathogenic | .008 | .37 |
| hsa.let.7b.5p | 0.294 | Pathogenic | .009 | .37 |
Abbreviations: BPV, whole-brain parenchymal volume; cGMV, cortical gray matter volume; EDSS, Expanded Disability Status Scale; miRNA, microRNAs; MRI, magnetic resonance imaging; T1:T2, ratio of T1 hypointense to T2 hyperintense lesion volume; T2LV, T2 hyperintense lesion volume; UCCA, upper cervical spinal cord area.
Estimated Spearman correlation coefficients are shown: the sign of the Spearman correlation indicates the direction of association between the miRNA expression level and the MRI measure of disease activity; its value reflects the strength of the association. In the interpretation of the meaning of the correlation coefficients, MRI-indicated severity was reflected in 2 possible directions: (1) for lesion severity (T2LV, T1:T2 ratio), a higher number represented increased disease severity, and (2) for atrophy measures (BPV, cGMV, and UCCA), ahigher number represented lower disease severity (less atrophy). The miRNA-MRI associations were observed in either direction: (1) a pathogenic relationship shown by a higher miRNA expression was associated with greater severity of MRI-indicated involvement, and (2) a protective relationship shown by a higher miRNA expression was associated with lower severity of MRI-indicated involvement.
Corrected for multiple comparisons using false discovery rate.